BiotechTube

Botulinum toxin type A + Botulinum toxin type A + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nervous System Disorders

Conditions

Nervous System Disorders

Trial Timeline

Aug 1, 2011 → Sep 1, 2013

NCT ID
NCT01313299

About Botulinum toxin type A + Botulinum toxin type A + Placebo

Botulinum toxin type A + Botulinum toxin type A + Placebo is a phase 3 stage product being developed by Ipsen for Nervous System Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01313299. Target conditions include Nervous System Disorders.

What happened to similar drugs?

0 of 7 similar drugs in Nervous System Disorders were approved

Approved (0) Terminated (0) Active (7)
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄temozolomideMerckPhase 3
🔄leflunomide + procarbazine hydrochloridePfizerPhase 3
🔄Gadobutrol (Gadavist, Gadovist, BAY86-4875) + MagnevistBayerPhase 3
🔄Gadobutrol (Gadavist, Gadovist, BAY86-4875)BayerPhase 3
🔄Botulinum toxin type AIpsenPhase 3
🔄EryDex Low dose DSP + EryDex High dose DSP + Pooled PlaceboQuince TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01313299Phase 3Completed
NCT01261611Phase 3Completed
NCT01333397Phase 2Completed

Competing Products

20 competing products in Nervous System Disorders

See all competitors
ProductCompanyStageHype Score
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcoholEisaiPhase 1
29
perampanelEisaiPhase 2
35
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
42
TirabrutinibOno PharmaceuticalPhase 1
36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
39
pemetrexedEli LillyPhase 1
29
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
42
AcalabrutinibAstraZenecaPhase 2
39
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
Avelumab + LenvatinibMerckPhase 1
33
temozolomideMerckPhase 3
44
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
39
TemozolomideMerckPhase 2
35
AEE788 + everolimusNovartisPhase 1/2
32
vatalanibNovartisPhase 2
35
EPO906 (epothilone B)NovartisPhase 1
29